Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿ø¹ß¼º °£¾Ï¿¡ ´ëÇÑ Á¤À§ ¹æ»ç¼±Ä¡·áÀÇ ¿¹ºñ°á°ú Preliminary Result in Patients with Primary Hepatoma treated by Stereotactic Radiotherapy

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2001³â 19±Ç 1È£ p.34 ~ 39
¼Ò¼Ó »ó¼¼Á¤º¸
°­±â¹®/Ki Mun Kang ÃÖÀϺÀ/±èÀξÆ/ÃÖº´¿Á/°­¿µ³²/ä±Ô¿µ/ÇѼºÅÂ/Á¤±Ô¿ø/Ihl Bohng Choi/In An Kim/Byung Ock Choi/Young Nam Kang/Gyu Young Chai/Sung Tae Han/Gyu Won Chung

Abstract

¸ñÀû: °£¾ÏÀ» ´ë»óÀ¸·Î ÇÑ °í½ÄÀûÀÎ ¹æ»ç¼±Ä¡·á°¡ ¾Æ´Ñ Á¤À§¹æ»ç¼±Ä¡·á¿¡ ´ëÇÑ º¸°í´Â ¸Å¿ì µå¹°´Ù. ÀÌ¿¡ ÀúÀÚµéÀº ¿ø¹ß¼º °£¾ÏȯÀÚµéÀ» ´ë»óÀ¸·Î Á¤À§¹æ»ç¼±Ä¡·á¿¡ ´ëÇÑ ¿¹ºñ°á°ú¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý: 1999³â 7¿ùºÎÅÍ 2000³â 3¿ù±îÁö ¼º¸ðº´¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ µÎ°³¿Ü Á¾¾çÀ¸·Î
Á¤À§¹æ»ç¼±Ä¡·á¸¦ 33¸íÀÇ È¯Àڵ鿡¼­ ½ÃÇàÇÏ¿´À¸¸ç ±×Áß 13¸íÀÇ ¿ø¹ß¼º °£¾ÏȯÀÚµéÀ» ´ë»ó
À¸·Î ÇÏ¿´´Ù. ´ë»óȯÀÚµéÀÇ ¼ºº°Àº ³²ÀÚ°¡ 12¸í, ¿©ÀÚ°¡ 1¸íÀ̾úÀ¸¸ç ¿¬·ÉºÐÆ÷Àº 44~66¼¼(Áß
¾Ó°ª : 59¼¼)¿´°í Á¾¾çÀÇ Å©±â´Â 10~825 cc (Æò±Õ : 185 cc)¿´´Ù. Á¤À§¹æ»ç¼±Ä¡·á´Â 1ȸ 3~5
Gy¸¦ 90%ÀÇ µî¼±·® °î¼±¿¡ ±âÁØÇÏ¿© ÁÖ 3~5ȸ¾¿, 2~3ÁÖ µ¿¾È Á¶»ç¼±·®ÀÇ ¹üÀ§´Â 30~50 Gy
ÀÌ°í Áß¾Ó¼±·®Àº 50 Gy¿´´Ù.
°á°ú: ÃßÀû°üÂû±â°£Àº 3~13°³¿ùÀ̾ú´Ù(Áß°£ÃßÀû°üÂû±â°£: 8°³¿ù). Á¤À§¹æ»ç¼±Ä¡·á ÈÄ Àüü
ȯÀÚ¿¡¼­ ¿ÏÀü°üÇØ 7.7%, ºÎºÐ°üÇØ 53.8%, ¹Ì¼¼°üÇØ 30.8%, ¹«¹ÝÀÀ 7.7%¿´À¸¸ç ±¹¼ÒÁ¦¾îÀ²
(¿ÏÀü°üÇØ+ºÎºÐ°üÇØ)Àº 61.5%¿´´Ù. Ç÷û AFPÀÇ Ä¡·á Àü°ú Ä¡·á ÈÄ ¼öÄ¡ÀÇ º¯È£¸¦ ºñ±³ÇÑ
°á°ú, ÀüüȯÀÚ Áß 92.3%¿¡¼­ AFPÀÌ °¨¼ÒÇÏ¿´´Ù. Ä¡·á¿¡ µû¸¥ ºÎÀÛ¿ëÀº ¼ÒÈ­Àå¾Ö°¡ 84.6%,
°æÇÑ ¿À½ÉÀÌ 69.2%, ÀϽÃÀûÀÎ °£ ±â´ÉÀÇ ÀúÇÏ°¡ 15.4%, ¹Ì¿­ÀÌ 7.7%¿¡¼­ ³ªÅ¸³µÀ¸³ª Ä¡¸íÀû
ÀÎ ºÎÀÛ¿ëÀº ¾ø¾ú´Ù.
°á·Ð: ¿ø¹ß¼º °£¾Ï¿¡ ´ëÇÑ Á¤À§¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÑ °á°ú ºñ±³Àû ¾ÈÀüÇÏ°í È¿°úÀûÀÎ Ä¡·á¹æ
¹ýÀ̾ú´Ù. ±×·¯³ª »õ·Î¿î Ä¡·á¹æ¹ýÀ¸·Î¼­ °ËÁõÇϱâ À§Çؼ­´Â º¸´Ù ¸¹Àº ȯÀÚ¿Í Àå±âÀûÀÎ Ãß
Àû°üÂûÀÌ ÇÊ¿äÇϸ®¶ó°í »ç·áµÈ´Ù.

Purpose: It is not common to evaluate the response of the fractionated stereotactic radiotherapy (SRT) to primary hepatoma as compared with conventional radiotherapy. The purpose of the study was to take the preliminary result on the clinical
trial
of
primary hepatoma by SRT.
Materials and Methods: From July 1999 to March 2000, thirty three patients were
hospitalized in the St. Mary's Hospital, and treated with SRT for extracranial tumors.
Among them, 13 patients were diagnosed to primary hepatoma and then applied by
frameless SRT using 6 MV linac accelerator. There were 12 male and 1 female patients.
They had the age of 44~66 year old (median : 59) and the tumor size of 10~825 cc
(median : 185 cc). SRT was given to them 3~5 fractions a week (5 Gy/fraction, 90%
isodose line) for 2~3 weeks. Median dose of SRT was 50 Gy and the range was 30~50
Gy.
Results: Follow-up period ranged from 3 months to 13 months with median of 8
months. After treating SRT to thirteen patients with primary hepatoma, the response of
the tumor was examined by abdominal CT: they are classified by 1 complete regression
(7.7%), 7 partial regression (53.8%), 4 minimal regression (30.8%), 1 stable disease
(7.7%). The positive responses more than partial remission were 8 patients (61.5%) after
the treatment. The level of serum alpha-fetoprotein (AFP) after the treatment as
compared with pretreatment had been 92.3% decreased. There was no severe
complication except dyspepsia 84.6%, mild nausea 69.2%, transient decreased of hepatic
function 15.4% and fever 7.7%.
Conclusion: SRT to the patients with primary hepatoma was potentially suggested to
become the safe and more effective tool than the conventional radiotherapy even though
there were relatively short duration of follow-up and small numbers to be tested.

Å°¿öµå

¿ø¹ß¼º°£¾Ï; Á¤À§¹æ»ç¼±Ä¡·á; Primary hepatoma; Stereotactic radiotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS